PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $40,852,372 | -39.6% | 2,449,183 | 0.0% | 15.05% | -28.4% |
Q2 2023 | $67,646,434 | +20.1% | 2,449,183 | 0.0% | 21.00% | +14.6% |
Q1 2023 | $56,331,209 | +210712.5% | 2,449,183 | 0.0% | 18.32% | +135.7% |
Q4 2022 | $26,721 | -99.9% | 2,449,183 | 0.0% | 7.77% | +27.9% |
Q3 2022 | $20,647,000 | +6.6% | 2,449,183 | 0.0% | 6.08% | +22.8% |
Q2 2022 | $19,373,000 | -66.6% | 2,449,183 | 0.0% | 4.95% | -54.9% |
Q1 2022 | $57,997,000 | -30.8% | 2,449,183 | 0.0% | 10.96% | +15.0% |
Q4 2021 | $83,762,000 | +93.0% | 2,449,183 | 0.0% | 9.54% | +150.5% |
Q3 2021 | $43,400,000 | – | 2,449,183 | – | 3.81% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |